How should the CAP of 199 dB/m (S1 steatosis) and liver stiffness of 3.1 kPa (F1 fibrosis) be interpreted and managed?

Interpretation and Management of CAP 199 dB/m and Liver Stiffness 3.1 kPa

This patient has mild hepatic steatosis (S1) without significant fibrosis (F0), indicating early metabolic liver disease that requires lifestyle intervention but not hepatology referral or advanced surveillance. 1

Interpretation of Results

Steatosis Assessment (CAP 199 dB/m)

• CAP of 199 dB/m falls below all established thresholds for significant steatosis, indicating minimal to no hepatic fat accumulation 1
• The value is well below the 248 dB/m cutoff for mild steatosis (S1), below 268 dB/m for moderate steatosis (S2), and far below 280 dB/m for severe steatosis (S3) 1
• Values above 275 dB/m are required for >90% sensitivity in detecting steatosis in NAFLD, making this result reassuring 1
• The CAP IQR of 86 dB/m exceeds the proposed quality threshold of <40 dB/m, suggesting measurement variability that may affect accuracy 1

Fibrosis Assessment (LSM 3.1 kPa)

• Liver stiffness of 3.1 kPa definitively rules out advanced fibrosis (F3-F4) and cirrhosis 1, 2
• This value is substantially below the 8 kPa threshold used to exclude advanced fibrosis with 93% sensitivity 2
• The measurement falls in the F0 range (no fibrosis), well below 5.6 kPa for F1 (mild fibrosis) 3
• The E IQR of 0.3 kPa with an IQR/Median ratio of 10% indicates acceptable measurement quality 1

Clinical Management Algorithm

Immediate Actions

• No hepatology referral is required because LSM <8 kPa rules out advanced fibrosis, allowing management in primary care or endocrinology settings 2
• No hepatocellular carcinoma surveillance is needed as this is only indicated when LSM >12 kPa or confirmed cirrhosis is present 2
• No upper endoscopy for variceal screening since portal hypertension assessment is only recommended when LSM ≥12 kPa 4

Risk Factor Assessment and Modification

• Evaluate for metabolic syndrome components: measure fasting glucose, HbA1c, lipid panel, blood pressure, and calculate BMI 2
• Screen for secondary causes of liver disease: obtain hepatitis B surface antigen, hepatitis C antibody, iron studies, and alcohol use history 1
• Calculate FIB-4 score to complement the elastography findings; a FIB-4 <1.3 (or <2.0 if age ≥65 years) confirms low fibrosis risk 2

Lifestyle Intervention

• Target 7-10% body weight loss through diet and exercise as the most effective strategy to prevent fibrosis progression in metabolic liver disease 4, 2
• Implement cardiovascular risk reduction measures including management of diabetes, hypertension, and dyslipidemia 2
• Counsel on alcohol abstinence or limitation to minimize additional hepatic injury 1

Longitudinal Monitoring

• Repeat FibroScan every 2-3 years to monitor for progression of steatosis or development of fibrosis 2
• Monitor liver enzymes (ALT, AST) annually as part of routine metabolic screening 2
• Reassess metabolic parameters (glucose, lipids, weight) at regular intervals per standard diabetes/metabolic syndrome guidelines 2

Critical Pitfalls to Avoid

Measurement Quality Concerns

• The CAP IQR of 86 dB/m substantially exceeds the proposed quality threshold of <30-40 dB/m, raising concerns about measurement reliability 1
• Consider repeating the examination after at least 3 hours of fasting to improve CAP accuracy 2
• Verify that the appropriate probe (M vs XL) was used based on BMI and skin-to-liver capsule distance; XL probe is indicated for BMI ≥30 kg/m² 2

Interpretation Errors

• Do not over-interpret the S1 classification when CAP is actually 199 dB/m, which is below the 248 dB/m threshold for S1 steatosis 1, 3
• Recognize that CAP has suboptimal performance for quantifying steatosis grades, with AUROC of only 0.70-0.77 for distinguishing S1 from higher grades 1
• Be aware that advanced fibrosis (≥F3) can falsely elevate CAP values in patients without true steatosis, though this is not relevant at LSM 3.1 kPa 5

Clinical Context

• CAP does not predict liver-related outcomes or mortality; it solely reflects fat content and should not drive prognostic discussions 2
• Ultrasound remains the preferred first-line imaging for steatosis detection despite CAP availability; consider confirmatory ultrasound if clinical suspicion differs from CAP result 1
• If metabolic risk factors are present despite reassuring elastography, continue aggressive metabolic management as subclinical disease may still progress 2